Neurofibromatosis type 2 in the otorhinolaryngological practice
- 20 March 2024
- journal article
- case report
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 89 (1) , 37-41
Abstract
Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disease (frequency 1 in 25-90 000) characterized by the formation of tumors of the central nervous system due to a mutation in the NF2 gene on chromosome 22q12. Bilateral vestibular schwannomas are recognized as absolute diagnostic criteria of NF2 and occur in 95% of patients, are accompanied by hearing impairment, manifest at the age of 18-24 years. Skin manifestations can precede vestibular schwannomas for several years and predict the course of the disease: neurofibromas, cafe-au-lait macules, hypopigmented spots, recently described mesh capillary malformations. Despite the benign nature of schwannomas, they can lead to hearing loss, vestibular dysfunction, facial nerve paralysis, gait disorders, pain and convulsions, there is a risk of early death from compression of the brain stem. The probability of progressive hearing loss is partly determined by the type of mutation. We described a clinical case of NF2 in a 21-year-old patient with bilateral vestibular schwannomas without hearing loss, whose skin examination by ENT specialist revealed this disease. The importance of the presented observation is that the doctor should assume neurofibromatosis type 2 in a young patient with bilateral vestibular schwannomas. It is necessary to undertake a further examination of this patient, including: skin examination for the identification of characteristic neurofibromas and cafe-au-lait macules, consultation with an ophthalmologist, neurologist, MRI of the brain and spinal cord with contrast, genetic analysis — for timely initiation of therapy that prevents hearing loss and vestibular disorders.Keywords
This publication has 22 references indexed in Scilit:
- Skin lesions in neurofibromatosis type 2: diagnostic and prognostic significance of cutaneous (plexiform) schwannomasJournal of the European Academy of Dermatology and Venereology, 2022
- Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysisJournal of Neuro-Oncology, 2022
- Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomasLaryngoscope Investigative Otolaryngology, 2021
- The emerging role of hearing loss rehabilitation in patients with vestibular schwannoma treated with Gamma Knife radiosurgery: literature reviewNeurosurgical Review, 2020
- Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reportsNeurochirurgie, 2018
- Neurofibromatosis type 2 service delivery in EnglandNeurochirurgie, 2018
- Early Genetic Diagnosis of Neurofibromatosis Type 2 From Skin Plaque Plexiform Schwannomas in ChildhoodJAMA Dermatology, 2018
- Neurofibromatosis type 22015
- Characterization of early onset neurofibromatosis type 2Brain and Development, 2014
- Empirical development of improved diagnostic criteria for neurofibromatosis 2Genetics in Medicine, 2011